High Gross MarginA near-41% gross margin provides durable pricing and cost buffer in pharma manufacturing. This margin supports investment in quality, regulatory compliance and product development, helping sustain profitability across product cycles and competitive pricing pressures.

Conservative Balance SheetVery low leverage and a high equity ratio give Orchid durable financial flexibility to fund capex, regulatory compliance and expansion without heavy refinancing. This reduces insolvency risk and supports long-term operational and strategic initiatives.

Diverse Pharma Business ModelA mix of API sales, finished formulations and contract manufacturing diversifies revenue, reduces customer concentration and leverages manufacturing scale. This structural diversification supports steady demand across domestic and export markets over the medium term.

Bears Say

Negative Free Cash FlowNegative free cash flow and weak cash conversion (OCF/net income ~0.19) limit internal funding for capex, working capital and growth. Persisting cash strain could force external financing, constrain R&D or manufacturing investments, and elevate liquidity risk.

Volatile EarningsA steep EPS decline signals earnings volatility that weakens predictability for reinvestment and stakeholder planning. Large EPS swings can reflect margin pressure, one-offs, or operational issues, complicating long-term capital allocation and performance visibility.

Moderate Return & Efficiency HeadroomROE under 8% and mid-teens EBITDA margin point to modest return generation relative to capital employed. This suggests limited efficiency or pricing upside and means management must improve operations or portfolio mix to drive sustainably higher shareholder returns.

Orchid Pharma Limited News

Orchid Pharma’s 32nd AGM: Virtual Meeting and Voting Results Announced

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has issued an update. Orchid Pharma Limited announced the results of its...

5M ago

ORCHPHARMA FAQ

What was Orchid Pharma Limited’s price range in the past 12 months?

Orchid Pharma Limited lowest stock price was ₹603.80 and its highest was ₹1065.15 in the past 12 months.

What is Orchid Pharma Limited’s market cap?

Orchid Pharma Limited’s market cap is ₹33.90B.

When is Orchid Pharma Limited’s upcoming earnings report date?

Orchid Pharma Limited’s upcoming earnings report date is May 07, 2026 which is in 73 days.

How were Orchid Pharma Limited’s earnings last quarter?

Orchid Pharma Limited released its earnings results on Feb 11, 2026. The company reported -₹2.487 earnings per share for the quarter, missing the consensus estimate of -₹0.3 by -₹2.187.

Is Orchid Pharma Limited overvalued?

According to Wall Street analysts Orchid Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orchid Pharma Limited pay dividends?

Orchid Pharma Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Orchid Pharma Limited dividends here

What is Orchid Pharma Limited’s EPS estimate?

Orchid Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Orchid Pharma Limited have?

Orchid Pharma Limited has 50,719,105 shares outstanding.

What happened to Orchid Pharma Limited’s price movement after its last earnings report?

Orchid Pharma Limited reported an EPS of -₹2.487 in its last earnings report, missing expectations of -₹0.3. Following the earnings report the stock price went up 0.189%.

Which hedge fund is a major shareholder of Orchid Pharma Limited?

Currently, no hedge funds are holding shares in IN:ORCHPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Orchid Pharma Limited

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company's multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. In addition, the company provides liaising support to customers in regulatory, pharma covigilance, testing and release, retention of samples, service providers, and business development. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited is a subsidiary of Dhanuka Laboratories Limited.